title: NF-κB p65 phosphorylated at serine-536 is an independent prognostic factor in Swedish colorectal cancer patients.
abstract: BACKGROUND
  The NF-κB transcription factor protein family has diverse cellular and biological functions, and posttranslational modification is important to regulate these functions. An important site of phosphorylation of NF-κB p65 subunit is at serine-536 (phospho-Ser536-p65), and this phosphorylation is involved in regulation of transcriptional activity, nuclear localization, and protein stability.
  
  
  METHODS
  In this study, we investigated expression of phospho-Ser536-p65 in colorectal cancers and its relationships with clinicopathological factors. The expression of phospho-Ser536-p65 was examined by immunohistochemistry in 203 primary colorectal cancers, 156 normal mucosa specimens, and 18 metastases in the lymph nodes.
  
  
  RESULTS
  The expression of phospho-Ser536-p65 increased from normal mucosa to primary tumor (p < 0.0001). Further, the increased expression of phospho-Ser536-p65 in the cytoplasm of the primary tumors correlated with worse survival of the patients independently of gender, age, tumor location, stage, and differentiation (p = 0.04; hazard ratio, 1.89; 95% CI 1.03-3.47).
  
  
  CONCLUSIONS
  The NF-κB p65 subunit phosphorylated at serine-536 is an independent prognostic factor in colorectal cancer patients.
authors.affiliation: Division of Oncology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, SE-581 85, Linköping, Sweden.
authors.forename: Andreas
authors.initials: A
authors.lastname: Lewander
authors.forename: Jinfang
authors.initials: J
authors.lastname: Gao
authors.forename: John
authors.initials: J
authors.lastname: Carstensen
authors.forename: Gunnar
authors.initials: G
authors.lastname: Arbman
authors.forename: Hong
authors.initials: H
authors.lastname: Zhang
authors.forename: Xiao-Feng
authors.initials: XF
authors.lastname: Sun
mesh_terms: D002467:Cell Nucleus / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D003593:Cytoplasm / Q000378:metabolism; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism / Q000473:pathology; D008207:Lymphatic Metastasis; D015999:Multivariate Analysis; D010766:Phosphorylation; D010768:Phosphoserine / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D013194:Staining and Labeling; D016019:Survival Analysis; D013548:Sweden; D051996:Transcription Factor RelA / Q000378:metabolism*
chemical_list: D051996:Transcription Factor RelA; D010768:Phosphoserine
references.citation: Trends Biochem Sci. 2005 Jan;30(1):43-52
references.pmid: 15653325
references.citation: Curr Cancer Drug Targets. 2009 Jun;9(4):566-71
references.pmid: 19519322
references.citation: Genes Dev. 1995 Nov 15;9(22):2723-35
references.pmid: 7590248
references.citation: J Cell Sci. 2005 Oct 15;118(Pt 20):4589-92
references.pmid: 16219681
references.citation: Clin Cancer Res. 1999 Jan;5(1):119-27
references.pmid: 9918209
references.citation: Surgery. 2001 Aug;130(2):363-9
references.pmid: 11490372
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Gastroenterol Clin North Am. 2010 Sep;39(3):601-13
references.pmid: 20951919
references.citation: J Biol Chem. 1999 Oct 22;274(43):30353-6
references.pmid: 10521409
references.citation: Semin Oncol. 2001 Dec;28(6):626-33
references.pmid: 11740821
references.citation: Biochem J. 2004 Sep 1;382(Pt 2):393-409
references.pmid: 15214841
references.citation: J Biol Chem. 2004 Dec 31;279(53):55633-43
references.pmid: 15489227
references.citation: Oncology. 2003;65(1):37-45
references.pmid: 12837981
references.citation: Nature. 2005 Apr 28;434(7037):1138-43
references.pmid: 15858576
references.citation: J Biol Chem. 2002 Feb 8;277(6):3863-9
references.pmid: 11733537
references.citation: Histol Histopathol. 2007 Dec;22(12):1387-98
references.pmid: 17701919